SLU-PP-332 500mcg per tablet*10vials

▎Slu-PP-332 Structure

▎Slu-PP-332 Research

Research Background of Slu-PP-332 

With the continuous rise in the incidence of metabolic diseases such as obesity, type 2 diabetes, and heart failure worldwide, as well as issues like muscle function decline and reduced exercise capacity caused by aging populations, developing drugs that mimic the beneficial effects of exercise has become a key direction in medical research. Exercise improves bodily functions by activating energy metabolism pathways, promoting mitochondrial biogenesis, and regulating skeletal muscle fiber type transformation. However, there is a wide population with insufficient physical activity, including the elderly, myopathy patients, and those with motor dysfunction, who urgently need drug interventions to trigger exercise-like cellular adaptive changes. Estrogen-related receptors (ERRs), as members of the nuclear receptor superfamily, play a core role in regulating mitochondrial function, fatty acid oxidation, and skeletal muscle metabolic phenotypes. The development of ERR agonists provides a scientific basis for targeting key molecules in exercise-mimicking drugs. 

Based on the structural characteristics and functional mechanisms of ERRs, research teams have successfully developed the novel ERR agonist Slu-PP-332 through computer-aided drug design, high-throughput screening, and structure-activity relationship optimization. This molecule efficiently binds to and activates three ERR subtypes (ERRα, ERRβ, ERRγ), with high selectivity for ERRα. It induces conformational changes to recruit coactivators, initiating downstream gene transcription programs related to energy metabolism, mitochondrial biogenesis, and skeletal muscle oxidative phenotypes. Preclinical studies have shown that Slu-PP-332 significantly improves energy expenditure and insulin sensitivity in obese animal models, enhances cardiometabolic function in heart failure models, and promotes the transformation of skeletal muscle toward oxidative fibers, providing innovative intervention strategies for metabolic diseases, cardiac diseases, and motor function-related disorders and advancing translational medicine research from basic target discovery to drug development. 

Source:ACS[4]

What is the mechanism of action of Slu-PP-332? 

Regulation of Energy Metabolism 

Enhanced Energy Expenditure: Upon activating ERRs, Slu-PP-332 upregulates the expression of genes involved in energy metabolism, promoting intracellular energy metabolic processes and enabling the body to consume more energy. For example, in skeletal muscle cells, it activates the genetic program of acute aerobic exercise, enhancing mitochondrial function and cellular respiration, thereby improving energy utilization efficiency and inducing a negative energy balance to aid in weight loss^[1,2].

Promoted Fatty Acid Oxidation: This agonist enhances fatty acid oxidation, facilitating the transport of more fatty acids from adipose tissue to mitochondria for oxidative breakdown and providing energy to the body. This process reduces fat accumulation and effectively decreases fat mass. Studies have found that after administering Slu-PP-332 to mice, their fatty acid oxidation significantly increased, with reduced fat mass accumulation^{[1, 3]} .

Improvement of Skeletal Muscle Function 

Increased Mitochondrial Function: In skeletal muscle cell lines, Slu-PP-332 enhances mitochondrial function and cellular respiration. It induces the expression of genes related to mitochondrial biogenesis and function, increasing mitochondrial quantity and activity, thereby improving cellular aerobic metabolism capacity, providing more energy for muscle contraction, and enhancing muscle endurance^{[3, 4]}. 

Altered Skeletal Muscle Fiber Type: Slu-PP-332 increases the proportion of type IIa oxidative skeletal muscle fibers. Type IIa fibers have high aerobic metabolic capacity, and their increased proportion helps improve muscle endurance and exercise capacity. Experiments have shown that after administering Slu-PP-332 to mice, their exercise endurance significantly improved^[4]. 

Impact on Metabolic Syndrome 

Alleviated Obesity: In diet-induced obesity or mouse models, Slu-PP-332 effectively alleviates obesity by regulating energy metabolism and reducing fat accumulation. Its effects of increasing energy expenditure and promoting fatty acid oxidation lead to weight loss and reduced fat mass in mice, thereby improving obesity-related metabolic disorders^[1]. 

Improved Insulin Sensitivity: Insulin resistance is a key feature of metabolic syndrome. Slu-PP-332 improves insulin sensitivity, enhancing the body’s response to insulin and better regulating blood glucose levels. This may occur through molecular mechanisms related to insulin signaling pathways, though specific sites of action and signal transduction pathways require further study. Nevertheless, this effect is of great significance for the prevention and treatment of type 2 diabetes ^[1]. 

Regulation of Cardiac Function 

Improved Cardiometabolic Function: Estrogen receptor-related orphan receptors ERRα and ERRγ are important regulators of cardiac metabolism. As an ERR agonist, Slu-PP-332 activates ERRγ, upregulating the expression of genes related to oxidative phosphorylation and fatty acid metabolism pathways, promoting cardiac fatty acid metabolism and mitochondrial function, maintaining normal cardiac energy supply, and thus improving cardiac function. In a mouse model of heart failure induced by pressure overload, Slu-PP-332 treatment significantly increased ejection fraction, improved mitochondrial ultrastructure, and reduced cardiac fibrosis ^[5,7]. 

Regulation of Cell Cycle and Developmental Pathways: Slu-PP-332 also induces downregulation of cell cycle genes in cardiomyocytes, a process partially mediated by E2F1. Regulation of the cell cycle may influence cardiomyocyte proliferation and hypertrophy, and the positive effects of Slu-PP-332 on cardiac metabolism and function indicate its potential value in heart failure treatment ^[5]. 

What are the applications of Slu-PP-332? 

In Metabolic Diseases 

Treatment of Obesity: Slu-PP-332 activates ERRs to enhance energy expenditure, promote fatty acid oxidation, and reduce fat accumulation. In studies on diet-induced obesity or ob/ob mice, administration of Slu-PP-332 significantly reduced fat mass accumulation, indicating its potential application in obesity treatment. Its mechanism of action may involve mimicking exercise-induced metabolic pathways to increase energy expenditure and reduce fat^[1,3]. 

Treatment of Type 2 Diabetes: In metabolic syndrome models, Slu-PP-332 not only effectively alleviates obesity but also improves insulin sensitivity. Improved insulin sensitivity is crucial for type 2 diabetes patients, as it aids in better blood glucose control. This suggests that Slu-PP-332 may have a positive impact on type 2 diabetes treatment by regulating metabolic processes^[1].  

The development of obesity promotes an increase in between ER and mitochondrias contacts in the liver, leading to mitochondria Ca⊃2;⁺ overload and oxidative damage and inflammation generation. 

Source: ELSEVIER ^[6]

In Exercise Function Improvement 

Enhanced Exercise Endurance: In mouse experiments, Slu-PP-332 increased type IIa oxidative skeletal muscle fibers, thereby enhancing exercise endurance. It activates genetic programs in skeletal muscle related to acute aerobic exercise, a process dependent on ERRα. By improving mitochondrial function and cellular respiration to mimic the effects of exercise, it enables the body to generate energy more efficiently during physical activity, enhancing exercise endurance. This has potential applications for athletes to improve performance, ordinary individuals to enhance exercise capacity, and the elderly to strengthen muscle function and maintain mobility^[2]. 

As an Exercise Mimetic: Given its ability to activate exercise-induced metabolic pathways, Slu-PP-332 can serve as an exercise mimetic. For individuals unable to engage in regular exercise due to health reasons (e.g., chronic diseases, mobility impairments, or rehabilitation patients), it offers a potential alternative to achieve exercise-like physiological benefits, such as improved metabolism and enhanced muscle function^[2]. 

In Cardiac Diseases 

Treatment of Heart Failure: Cardiometabolic dysfunction is a key feature of heart failure, and ERRα and ERRγ are critical regulators of cardiac metabolism. In experiments on adult male mice, synthetic Slu-PP-332 significantly improved ejection fraction and mitochondrial ultrastructure, reduced Nppa/Nppb expression, and alleviated cardiac fibrosis in mice with heart failure induced by transverse aortic constriction (TAC). Although it did not prevent cardiac hypertrophy, it improved cardiac function by upregulating oxidative phosphorylation and fatty acid metabolism pathways and enhancing mitochondrial function and fatty acid metabolism. This suggests that Slu-PP-332 holds promise as a potential drug for heart failure treatment, offering new therapeutic options for patients ^{[5, 7]}. 

Cardiometabolic Regulation: Further studies indicate that the cardiometabolic regulatory effects of Slu-PP-332 are primarily mediated by ERRγ. It activates a series of gene transcriptions related to fatty acid metabolism and mitochondrial function, optimizing cardiac metabolic processes and maintaining normal cardiac function. This precise regulation of cardiac metabolism provides new targets and directions for treating diseases associated with cardiometabolic disorders^{[5, 7]}. 

Conclusion 

Slu-PP-332 is an ERR agonist with broad medical applications. By activating ERRs, it regulates energy metabolism for the treatment of metabolic diseases such as obesity and type 2 diabetes, promotes fatty acid oxidation, and improves insulin resistance. It also enhances cardiometabolic function for heart failure treatment and boosts exercise endurance by mimicking exercise-induced metabolic pathways, providing new directions for related disease therapy and sports health management.

About The Author

The above-mentioned materials are all researched, edited and compiled by Cocer Peptides.

Scientific Journal Author

Xu Weiyi is a distinguished scholar with extensive expertise across various academic domains. Affiliated with numerous prestigious institutions such as Beijing Jiaotong University, Changchun University of Technology, East University of Science & Technology, Harvard Medical School, and Wenzhou Medical University, Xu has made significant contributions to the fields of Engineering, Biochemistry & Molecular Biology, Pharmacology & Pharmacy, and Cell Biology. His work spans from fundamental scientific research to applied areas like Medical Regulatory Science and Clinical In Vitro Diagnostic Technology, reflecting his profound expertise in integrating research with practical applications. Xu Weiyi is listed in the reference of citation [7].

▎Relevant Citations

[1]   Billon C, Schoepke E, Avdagic A, et al. A Synthetic ERR Agonist Alleviates Metabolic Syndrome[J]. Journal of Pharmacology and Experimental Therapeutics, 2024,388(2):232-240.DOI:10.1124/jpet.123.001733.

[2]   Billon C, Sitaula S, Banerjee S, et al. A Synthetic ERR$\alpha$ Agonist Induces an Acute Aerobic Exercise Response and Enhances Exercise Capacity[J]. BioRxiv, 2022. https://api.semanticscholar.org/CorpusID:252819965.

[3]   Nasri H. New hopes on "SLU-PP-332" as an effective agent for weight loss with indirect kidney protection efficacy; a nephrology point of view[J]. Journal of Renal Endocrinology, 2024. https://api.semanticscholar.org/CorpusID:267189187.

[4]   Billon C, Sitaula S, Banerjee S, et al. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity[J]. ACS Chemical Biology, 2023,18(4):756-771.DOI:10.1021/acschembio.2c00720.

[5]   Xu W, Billon C, Li H, et al. Novel ERR pan-agonists ameliorate heart failure through boosting cardiac fatty acid metabolism and mitochondrial function[J]. BioRxiv, 2022. https://api.semanticscholar.org/CorpusID:246945715.

[6]   Cárdenas-Pérez R E, Camacho A. Roles of calcium and Mitochondria-Associated Membranes in the development of obesity and diabetes[J]. Medicina Universitaria, 2016,18(70):23-33.DOI:10.1016/j.rmu.2015.10.004.

[7]   Xu W, Billon C, Li H, et al. Abstract 9682: The Cardiac Protective Effects of Novel Synthetic Pan-Estrogen Related Receptor Agonists Slu-pp-332 and Slu-pp-915[J]. Circulation, 2021,144.DOI:10.1161/circ.144.suppl_1.9682.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE SOLELY FOR INFORMATION DISSEMINATION AND EDUCATIONAL PURPOSES.  

The products provided on this website are intended exclusively for in vitro research. In vitro research (Latin: *in glass*, meaning in glassware) is conducted outside the human body. These products are not pharmaceuticals, have not been approved by the U.S. Food and Drug Administration (FDA), and must not be used to prevent, treat, or cure any medical condition, disease, or ailment. It is strictly prohibited by law to introduce these products into the human or animal body in any form.